FIELD: biotechnology.
SUBSTANCE: disclosed are methods of treating cancer expressing CEACAM5, which include 3 to 6 cycles of administration, where one cycle involves: administering an immunoconjugate containing an anti-CEACAM5 antibody in dose of 60 mg/m2 to 210 mg/m2 at least once during a cycle and administering trifluridine and tipiracil (TAS-102) in dose of 10 mg/m2 to 100 mg/m2, where TAS-102 contains trifluridine and tipiracil in molar ratio of 1:0.4 to 1:0.6, at least once during the cycle.
EFFECT: invention is used to treat cancer.
18 cl, 2 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER | 2020 |
|
RU2828374C2 |
| BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | 2020 |
|
RU2832083C2 |
| ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF | 2010 |
|
RU2575612C2 |
| ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS | 2014 |
|
RU2696579C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| ANTI-FOLR1 IMMUNOCONJUGATE APPLICATION SCHEMES | 2014 |
|
RU2801307C1 |
| CD138-TARGETED CELL AGENTS AND USING THEM | 2008 |
|
RU2537265C2 |
| METHOD FOR IMPROVING TARGETED ACTION OF CD138 EXPRESSING TUMOUR CELLS AND AGENTS TO THIS EFFECT | 2008 |
|
RU2486203C2 |
| ANTI-CD138 IMMUNOCONJUGATES AND USING THEM | 2008 |
|
RU2547939C2 |
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
